Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6620430 | 0.82 | POLA1 (0.65) | POLA1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL6413852 | 0.80 | ALDH1A1 (0.44) | POLA1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL6780896 | 0.79 | ALDH1A1 (0.43) | POLA1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL6732348 | 0.78 | POLA1 (0.71) | POLA1ALDH1A1RAB9AKCNH2KMT2A | |
| SCHEMBL6781920 | 0.75 | ALDH1A1 (0.39) | POLA1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL6776971 | 0.74 | ALDH1A1 (0.45) | POLA1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL6779854 | 0.73 | CNR2 (0.47) | POLA1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL6814201 | 0.73 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL7929460 | 0.72 | ALDH1A1 (0.48) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL6728870 | 0.71 | POLA1 (0.66) | POLA1ALDH1A1TSHRRAB9AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029879-A1 | Heterocycle carboxamides as antiviral agents | ANDERSON DAVID JOHN (US) | 2004-02-12 | — | — | US | disclosed |
| US-6624159-B2 | Herpes virus | PHARMACIA & UPJOHN COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6608082-B1 | Treatment of erectile dysfunction using isoquinoline compound melanocortin receptor ligands | LION BIOSCIENCE AG (DE) | 2003-08-19 | — | — | US | disclosed |
| US-20020025959-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029879-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | POLA1 267/4885ALDH1A1 779/4885KDM4E 201/4885 |
| US-20020025959-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | POLA1 267/4885ALDH1A1 779/4885KDM4E 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.